Type your tag names separated by a space and hit enter

Acetylcysteine and carbocysteine for acute respiratory tract infections in children

Evidence Summaries

Level of Evidence = D

Acetylcysteine and carbocysteine might possibly have limited efficacy and appear to be safe in the treatment of acute respiratory tract infections in children older than two years, but the evidence is insufficient. The quality of evidence is downgraded by study limitations (lack of/unclear allocation concealment and blinding), by inconsistency (variability in results), and by imprecise results (few patients and wide confidence intervals).

A Cochrane review 1 included 6 studies with a total of 497 children to study efficacy. They showed some benefit (e.g. reduction of cough at day 7) from mucolytic agents, although differences were of little clinical relevance. Data for infants younger than 2 years were unavailable. Thirty-four studies including the previous 6 trials were eligible to study safety (n=2064). Overall safety was good but very few data were available to evaluate safety in infants younger than 2 years. However, 59 cases of paradoxically increased bronchorrhoea observed in infants were reported to the French pharmacovigilance system 2 .

Regarding children younger than 2 years old, there are strong concerns about the safety of acetylcysteine and carbocysteine (increased instead of decreased bronchial secretions). These concerns led to the withdrawal of their licence in this age group in France and Italy in 2010. Therefore, these drugs should only be used for acute respiratory tract infections in neonates and infants in the context of a randomised controlled trial.

References

1. Chalumeau M, Duijvestijn YC. Acetylcysteine and carbocysteine for acute upper and lower respiratory tract infections in paediatric patients without chronic broncho-pulmonary disease. Cochrane Database Syst Rev 2013;(5):CD003124.  [PMID:23728642].

2. Mallet P, Mourdi N, Dubus JC et al. Respiratory paradoxical adverse drug reactions associated with acetylcysteine and carbocysteine systemic use in paediatric patients: a national survey. PLoS One 2011;6(7):e22792.  [PMID:21818391]


Copyright © 2017 Duodecim Medical Publications Limited.
Acetylcysteine and carbocysteine for acute respiratory tract infections in children is a sample topic from the Evidence-Based Medicine Guidelines.

To view other topics, please or purchase a subscription.

Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Learn more.

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Acetylcysteine and carbocysteine for acute respiratory tract infections in children ID - 452808 BT - Evidence-Based Medicine Guidelines UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/452808/all/Acetylcysteine_and_carbocysteine_for_acute_respiratory_tract_infections_in_children PB - Duodecim Medical Publications Limited DB - Evidence Central DP - Unbound Medicine ER -